Identification and targeting of costimulation-resistant T cells in renal transplantation

American Journal of Transplantation

Volumn 11, Issue 1, 2011, Pages 8-9

  Farber, Donna L ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BELATACEPT;

EDITORIAL; EFFECTOR CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD28; DRUG RESISTANCE; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MICE; T-LYMPHOCYTES;

EID: 78650884685     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03361.x     Document Type: Editorial

References (5)

1. Macedo C, Orkis EA, Popescu I, et al,. Contribution of naive and memory T cell populations to the human alloimmune response. Am J Transplant 2009; 9: 2057-2066.
2. Adams AB, Williams MA, Jones TR, et al,. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
3. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
4. Weaver TA, Charafeddine AH, Agarwal A, et al,. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746-749.
5. + effector memory T cells based on CD2 expression. Am J Transplant 2011; 11: 22-33.